Claims Scope:

Patent issued on June 7, 2022  

80% Sequence Identity – Compositions & Methods 

Application directed to inhibition of KIF11 expression. The application discloses treatment of diseases, including  cancers, through delivery of a modified mesenchymal stem cell product which expresses both a KIF11 small RNA and an exogenous KIF11 gene resistant to the small RNA, 80% identity to Seq Id Nos: 1, 2 or 3.